Know Labs Corp (KNW): רווח נקי למניה (EPS TTM)

Optimizing home delivery of diagnostic devices reduces costs, as confirmed by the 12-month rolling EPS value provided by the GURU.Markets website, while -4.92 characterizes this valuation parameter for Know Labs, Inc. (KNW); meanwhile, the massive potential of the diabetic market promises rapid growth, although skepticism regarding management transparency will persist until successful FDA trials.

For Know Labs, Inc. (KNW), which develops patent-protected glucose biosensors, the trailing 12-month EPS serves as an indicator of technology monetization. This metric reflects the net income allocated per common share over a year. The calculation eliminates speculative noise, focusing instead on the business's actual earnings. The stability of the curve confirms the effectiveness of the FDA validation process. Growth in this value signals the transformation of a technological barrier into sustainable financial profit.